Oxford Gene Technology Grants Microarray Licence to Phalanx Biotech Group
News Oct 31, 2007
Oxford Gene Technology(OGT) and Phalanx Biotech Group have announced the completion of a licensing agreement granting Phalanx access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.
The granted licence will enable Phalanx Biotech to fabricate and sell arrays, including OneArray™ for gene expression profile studies, in the US.
Dr Michael Bennett, Vice President Licensing and Patents at OGT, said: “This is a significant deal as it is the first licence granted to a Taiwanese company and reflects OGT’s continuing portfolio expansion in Asia”.
Dr Luke Chen, Vice President of Sales & Marketing at Phalanx Biotech, added, “We have long admired the work of Professor Edwin Southern and this important agreement will help Phalanx Biotech in its mission to provide affordable microarray products to scientists for new gene expression studies and to validate their existing microarray results.”
The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE